Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 14 2020 - 02:33PM
Edgar (US Regulatory)
|
|
|
OMB APPROVAL
|
|
|
|
OMB Number:
3235-0058
|
|
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
|
Expires:
February 28, 2022
|
Estimated
average burden
|
|
|
|
hours per
response.......2.50
|
|
|
|
|
|
FORM
12b-25
|
SEC FILE NUMBER
|
|
0-28666
|
|
|
|
|
|
|
|
CUSIP NUMBER
|
|
NOTIFICATION
OF LATE FILING
|
024600
|
(Check one):
|
☐
|
Form
10-K
|
☐
|
Form
20-F
|
☐
|
Form
11-K
|
☑
|
Form
10-Q
|
☐
|
Form
10-D
|
☐
|
Form
N-SAR
|
☐
|
Form
N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Period Ended:
June 30,
2020
|
|
|
|
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 10-K
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 20-F
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 11-K
|
|
|
|
|
|
|
☐
|
Transition
Report on Form 10-Q
|
|
|
|
|
|
|
☐
|
Transition
Report on Form N-SAR
|
|
|
|
|
|
|
|
|
For the Transition Period
Ended:
|
|
|
Nothing
in this form shall be construed to imply that the Commission has
verified any information contained herein.
|
If the
notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification
relates:
|
|
|
PART
I — REGISTRANT INFORMATION
|
American
Bio Medica Corporation
|
|
Full
Name of Registrant
|
|
N/A
|
|
Former
Name if Applicable
|
|
122 Smith Road
|
|
Address
of Principal Executive Office (Street and Number)
|
|
Kinderhook, New York 12106
|
|
City,
State and Zip Code
|
PART II — RULES 12b-25(b) AND
(c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks
relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
☑
|
(a)
|
The
reason described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense
|
|
|
|
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date;
and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
|
|
|
|
PART
III – NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K,
10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion
thereof, could not be filed within the prescribed time
period.
(Attach
extra Sheets if Needed)
As
indicated in a Form 8-K filed with the Commission on May 14, 2020,
American Bio Medica Corporation (the “Registrant”) relied on the
order (the “SEC Order”) issued by the Securities and Exchange
Commission (the “SEC”) on March 25, 2020 (Release No. 34-88465)
pursuant to the SEC’s authority under Section 36 of the Securities
Exchange Act of 1934 (the “Exchange Act”) granting exemptions from
certain provisions of the Exchange Act and the rules thereunder
related to the reporting requirements for certain public companies,
subject to the satisfaction of certain conditions, to delay the
filing of its Quarterly Report on Form 10-Q for the period ended
March 31, 2020 (“Form 10-Q”). Using the extension afforded under
the SEC Order, the Registrant was to file its Form 10-Q by June 29,
2020. The Registrant filed its Form 10-K for the year ended
December 31, 2020 on Friday, June 26, 2020 and filed its Form 10-Q
for the period ended March 31, 2020 on July 31, 2020.
Management has been
taking every effort with each filing (since the SEC order) to
restore its past solid record of compliance regarding its periodic
reports. Since the Registrant was unable to file its Form 10-Q for
the period ended March 31, 2020 until July 31, 2020, the Registrant
will not be able to file its Form 10-Q for the period ended June
30, 2020 by August 14, 2020 notwithstanding the level of expense or
effort.
The
Registrant is taking every effort to file the Form 10-Q within the
additional five (5) business days afforded under the filing of this
Form 12b-25, or by August 21, 2020. However, given the short period
of time since its last filing, management is unsure of whether it
will meet this extended filing date. If the Registrant is unable to
file by August 21, 2020, the Registrant does expect to file the
Form 10-Q for the period ended June 30, 2020 shortly after the
extended filing deadline.
PART
IV — OTHER INFORMATION
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|
|
Melissa A. Waterhouse
|
|
(518)
|
|
758-8158
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
|
Yes
|
☐
|
No
|
☑
|
|
|
|
|
The
Registrant did not file its Annual Report on Form 10-K for the year
ended December 31, 2019 until June 26, 2020. The Registrant did not
file its Quarterly Report on Form 10-Q for the quarter ended March
31, 2020 until July 31, 2020.
|
|
(3)
|
Is it
anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof?
|
Yes
|
☐
|
No
|
☑
|
|
|
|
If so,
attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
|
|
|
American
Bio Medica Corporation
|
|
(Name
of Registrant as Specified in Charter)
|
|
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
By:
|
/s/
Melissa A. Waterhouse
|
|
|
|
|
Name:
Melissa A. Waterhouse
|
|
|
|
|
Title:
Chief
Executive Officer/ Principal Financial Officer
|
3
American Bio Medica (QB) (USOTC:ABMC)
Historical Stock Chart
From Dec 2020 to Jan 2021
American Bio Medica (QB) (USOTC:ABMC)
Historical Stock Chart
From Jan 2020 to Jan 2021